Suppression of the secretion of @entity4090 , growth hormone and insulin-like growth factor 1 ( @entity442 ) might be important in the growth regulation and treatment of @entity0 . Because @entity2931 may counteract the anti- @entity5 effects of such treatment, the combination of an anti- @entity2931 ( @entity440 ), a @entity1943 analogue (octreotide) and a potent anti- @entity4090 (CV 205-502) might be attractive. In this respect, we performed a first exploratory long-term study on the feasibility of combined treatment and possible clear differences in endocrine and anti- @entity5 effects during such combined treatment vs standard treatment with @entity440 alone. Twenty-two post-menopausal @entity1 with metastatic @entity0 (ER and/or PR positive or unknown) were randomized to receive either 40 mg of @entity440 per day or the combination of 40 mg of @entity440 plus 75 microg of CV 205-502 orally plus 3 x 0.2 mg of @entity2390 s.c. as first-line endocrine therapy. An objective response was found in 36% of the @entity1 treated with @entity440 alone and in 55% of the @entity1 treated with combination therapy. Median time to progression was 33 weeks for @entity1 treated with @entity440 and 84 weeks for @entity1 treated with combination therapy, but the numbers are too small for hard conclusions. There was no difference in overall post-relapse survival between the two treatment arms. With respect to the endocrine parameters, there was a significant decrease of plasma @entity442 levels in both treatment arms, whereas during combined treatment plasma growth hormone tended to decrease and plasma @entity4090 levels were strongly suppressed; in some @entity1 insulin and @entity310 ( @entity7790 ) decreased during the triple therapy. Although there was no significant difference in mean decrease of plasma @entity442 levels between the two treatment arms, combined treatment resulted in a more uniform suppression of @entity442 . Therefore, the addition of a @entity1943 analogue and an anti- @entity4090 may potentially enhance the efficacy of anti- @entity2931 in the treatment of @entity0 owing to favourable endocrine and possible direct anti- @entity5 effects. Large phase III trials using depot formulations (to increase the feasibility) of @entity1943 analogues are warranted to demonstrate the potential extra beneficial anti- @entity5 effects of such combination therapy.

Feasibility, endocrine and anti- @entity5 effects of a triple endocrine therapy with @entity440 , a XXXX analogue and an antiprolactin in post-menopausal metastatic @entity0 : a randomized study with long-term follow-up.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer'] @entity440 :: ('MESH:D013629', 'Chemical') :: ['tamoxifen'] @entity2931 :: ('CHEBI:50114', 'Chemical') :: ['oestrogens', 'oestrogen'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumour'] @entity310 :: ('7124', 'Gene') :: ['transforming growth factor alpha'] @entity442 :: ('3479', 'Gene') :: ['IGF-1'] @entity7790 :: ('7039', 'Gene') :: ['TGF-alpha'] @entity4090 :: ('5617', 'Gene') :: ['prolactin'] @entity2390 :: ('MESH:D015282', 'Chemical') :: ['octreotide'] @entity1943 :: ('MESH:D013004', 'Chemical') :: ['somatostatin']
@entity1943 :: (MESH:D013004,Chemical) :: ['somatostatin']
